Generic placeholder image

Current Cardiology Reviews

Author(s): Prashanth Kulkarni*, Manjappa Mahadevappa and Srinivas Alluri

DOI: 10.2174/1573403X16666200621154842

DownloadDownload PDF Flyer Cite As
COVID-19 Pandemic and the Impact on the Cardiovascular Disease Patient Care

Page: [173 - 177] Pages: 5

  • * (Excluding Mailing and Handling)

Abstract

The COVID-19 pandemic has emerged as a serious global threat causing a large number of fatalities and putting enormous strain on the health care resources across the world. This has resulted in preferentially triaging the coronavirus infected patients and placing others, especially cardiovascular patients at increased risk for adverse complications. The effective management of cardiac patients in the hospital environment during this COVID-19 pandemic has emerged as a real challenge. We try to address this issue and also highlight the interplay between COVID-19 and cardiovascular diseases. We hereby review the available literature and emerging guidelines about cardiovascular implications related to COVID-19 which will have a bearing on the patient care, health care professionals and cardiac centres.

Keywords: COVID-19, cardiovascular, myocarditis, acute coronary syndrome, primary PCI, anxiety.

Graphical Abstract

[1]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[2]
World health organization, Coronavirus disease (COVID-19) outbreak situation. Avaiable from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019[May 19, 2020];.
[3]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[4]
Libby P. The heart in COVID19: Primary target or secondary bystander? JACC Basic Transl Sci 2020; 5(5): 537-42.
[http://dx.doi.org/10.1016/j.jacbts.2020.04.001.]
[5]
Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis 2020.
[http://dx.doi.org/10.1016/j.pcad.2020.03.001] [PMID: 32169400]
[6]
Oriol Rodríguez-Leor, Bethlehem Cid-Alvarez, Soledad Ojeda, etal. Impact of the COVID-19 pandemic on care activity in interventional cardiology in Spain. REC: Interven Cardiol 2020.
[http://dx.doi.org/10.24875/RECIC. M20000120.]
[7]
Wood S. The Mystery of the Missing STEMIs During the COVID-19 Pandemic 2020.April. Available from:. https://www.tctmd.com/news/mystery-missing-stemis-during-covid-19-pandemic
[8]
Garcia S, Albaghdadi MS, Meraj PM, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol 2020; 75(22): 2871-2.
[http://dx.doi.org/10.1016/j.jacc.2020.04.011] [PMID: 32283124]
[9]
Keesara S, Jonas A, Schulman K. Covid-19 and Health Care’s Digital Revolution. N Engl J Med 2020; 382(23)e82
[http://dx.doi.org/10.1056/NEJMp2005835] [PMID: 32240581]
[10]
Kunadian V. COVID-19: Providing ongoing care to patients with cardiovascular disease in a pandemic March 24, 2020 2020 https://www.pcronline.com/News/Whats-new-on-PCRonline/2020/COVID-19-Providing-ongoing-care-to-patients-with-cardiovascular-disease-in-a-pandemic[April 13, 2020];.
[11]
Welt FGP, Shah PB, Aronow HD, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: From the ACC’s interventional council and SCAI. J Am Coll Cardiol 2020; 75(18): 2372-5.
[http://dx.doi.org/10.1016/j.jacc.2020.03.021] [PMID: 32199938]
[12]
Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; 75(18): 2352-71.
[http://dx.doi.org/10.1016/j.jacc.2020.03.031] [PMID: 32201335]
[13]
Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: The protocols from Sichuan Provincial People’s Hospital. Intensive Care Med 2020; 46(6): 1111-13.
[http://dx.doi.org/10.1007/s00134-020-05993-9] [PMID: 32162032]
[14]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 28395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3.]
[15]
Tarantini G, Fraccaro C, Chieffo A, et al. Italian Society of Interventional Cardiology (GISE) position paper for cath lab-specific preparedness recommendations for healthcare providers in case of suspected, probable or confirmed cases of COVID-19. Catheter Cardiovasc Interv 2020.10.1002/ccd.28888..
[http://dx.doi.org/10.1002/ccd.28888]
[16]
Miller SL, Clements N, Elliott SA, Subhash SS, Eagan A, Radonovich LJ. Implementing a negative-pressure isolation ward for a surge in airborne infectious patients. Am J Infect Control 2017; 45(6): 652-9.
[http://dx.doi.org/10.1016/j.ajic.2017.01.029] [PMID: 28330710]
[17]
Medical Advisory Secretariat. Air cleaning technologies: An evidence-based analysis. Ont Health Technol Assess Ser 2005; 5(17): 1-52.
[PMID: 23074468]
[18]
Chow TT, Kwan A, Lin Z, Bai W. Conversion of operating theatre from positive to negative pressure environment. J Hosp Infect 2006; 64(4): 371-8.
[http://dx.doi.org/10.1016/j.jhin.2006.07.020] [PMID: 17046110]
[19]
Ing RJ, Barrett C, Chatterjee D, Twite M, Whitney GM. Perioperative preparations for COVID-19: The pediatric cardiac team perspective. J Cardiothorac Vasc Anesth 2020; S1053-0770(20)30391- 8.
[http://dx.doi.org/10.1053/j.jvca.2020.04.032] [PMID: 32451272]
[20]
CloroxPro. Cleaning & Disinfection Checklists for the Operating Room Available from: https://www.cloroxpro.com/resource-center/cleaning-and-disinfection-checklists-for-the-operating-room/
[21]
Matt P, Maisano F. Cardiac Surgery and the COVID-19 outbreak: what does it mean? 2020.Available from:. https://www.pcronline.com/News/Whats-new-on-PCRonline/2020/Cardiac-Surgery-and-the-COVID-19-outbreak-what-does-it-mean
[22]
Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc 2007.
[23]
KALETRA. (R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution Product Insert AbbVie Inc (per FDA). IL: North Chicago 2013.
[24]
DeCarolis DD, Westanmo AD, Chen YC, Boese AL, Walquist MA, Rector TS. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. Ann Pharmacother 2016; 50(11): 909-17.
[http://dx.doi.org/10.1177/1060028016660325] [PMID: 27465881]
[25]
Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2015; 79(5): 838-46.
[http://dx.doi.org/10.1111/bcp.12541] [PMID: 25377242]
[26]
Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: Pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol 2013; 76(3): 455-66.
[http://dx.doi.org/10.1111/bcp.12075] [PMID: 23305158]
[27]
Prescribing information; Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP 2011.07.
[28]
Product monographBrilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc. 2011.
[29]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[30]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[31]
Page RL II, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: A scientific statement from the american heart association. Circulation 2016; 134(6): e32-69.
[http://dx.doi.org/10.1161/CIR.0000000000000426] [PMID: 27400984]
[32]
Tönnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol 2013; 35(3): 434-42.
[http://dx.doi.org/10.3109/08923973.2013.780078] [PMID: 23635029]
[33]
Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020; 63(3): 364-74.
[http://dx.doi.org/10.1007/s11427-020-1643-8] [PMID: 32048163]